This phenomenon suggests that the combination of D-2HG and TMZ might explain why IDH1-mutant patients exhibit enhanced sensitivity to TMZ treatment with the combination showing therapeutic potential in glioma treatment. Here, IDH1 is linked to central nervous system cancer.